PMID- 2498034 OWN - NLM STAT- MEDLINE DCOM- 19890711 LR - 20190824 IS - 0010-7824 (Print) IS - 0010-7824 (Linking) VI - 39 IP - 4 DP - 1989 Apr TI - Effect of some oral contraceptives on serum concentrations of sex hormone binding globulin and ceruloplasmin. PG - 385-99 AB - Serum SHBG and ceruloplasmin (CP) concentrations were measured in women throughout a cycle of treatment with four oral contraceptives. In women receiving 150 micrograms levonorgestrel (LNG) daily both SHBG and CP decreased. SHBG also decreased, but CP increased, in women receiving ethynyloestradiol (EE) 30 micrograms with LNG 150 micrograms. In women taking 35 micrograms EE with either 600 micrograms or 1000 micrograms norethisterone, increases in CP were similar but SHBG increased more with the lower dose. Serum concentrations had not returned to pretreatment levels by eight days after cessation of dosing. The findings are compared with similar results for women taking 30 micrograms or 50 micrograms EE or an EE,LNG triphasic formulation. Serum concentrations of the gestagens were also measured. Increases in these concentrations when the gestagen was administered with EE to levels higher than expected from administration of the gestagen alone cannot be explained by increased binding to SHBG but are more likely to be due to changes in their metabolism. Differences in the responses of ostensibly closely related proteins of hepatic origin such as SHBG and CP to the oral contraceptives demonstrate that neither can be extrapolated to other pharmacodynamic responses. FAU - Song, S AU - Song S AD - Institute of Planned Parenthood Research, Shanghai, China. FAU - Chen, J K AU - Chen JK FAU - He, M L AU - He ML FAU - Fotherby, K AU - Fotherby K LA - eng PT - Comparative Study PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - United States TA - Contraception JT - Contraception JID - 0234361 RN - 0 (Contraceptives, Oral, Combined) RN - 0 (Sex Hormone-Binding Globulin) RN - 3J8Q1747Z2 (Norgestrel) RN - 423D2T571U (Ethinyl Estradiol) RN - 5W7SIA7YZW (Levonorgestrel) RN - EC 1.16.3.1 (Ceruloplasmin) RN - T18F433X4S (Norethindrone) SB - IM MH - Adult MH - Ceruloplasmin/*drug effects/metabolism MH - Contraceptives, Oral, Combined/*pharmacology MH - Ethinyl Estradiol/*pharmacology MH - Female MH - Humans MH - Levonorgestrel MH - Menstrual Cycle MH - Norethindrone/*pharmacology MH - Norgestrel/*pharmacology MH - Sex Hormone-Binding Globulin/*drug effects/metabolism OID - PIP: 055522 OID - POP: 00183740 OAB - 4 groups, each of 6 healthy volunteer female subjects aged 18-40 years, participated in this study designed to determine the effect of some contraceptive steroids on 2 plasma proteins -- sex hormone binding globulin (SHBG) and ceruloplasmin (CP). The pills were taken daily for 20 days, starting within the 1st 5 days of the menstrual cycle. There was no significant difference between the groups in the pre-treatment values. In Group LNG150 (150 mcg levonorgestrel), SHBG concentrations decreased, the decrease being statistically significant both in actual concentration and percentage change within 2-3 days of starting treatment. As pill-taking continued, SHBG concentrations declined further, and by the end of the treatment period they were less than half of the pretreatment value. Recovery was slow. In group EE30, LNG150 (ethinylestradiol 30 mcg and levonorgestrel 150 mg), no significant change occurred in SHBG concentrations during treatment. In Group EE35, NET1000 (ethinylestradiol 35 mcg and norethisterone 1000 mcg), SHBG increased, the value on days 2-3 of treatment being significantly higher than pretreatment. A steady state appeared to have been reached by days 7-8 and for the remainder of the treatment period the increase varied from 180-200% of the pretreatment value. The return to pretreatment values was slow. Women in Group EE35, NET600 (ethinylestradiol 35 mcg and norethisterone 600 mcg) also showed a rise in SHBG concentrations, which was greater than that observed in Group EE35, NET1000. In Group LNG150, CP concentrations slowly decreased during pill-taking, but the decrease did not reach statistical significance until days 14-15 of treatment; at this time the concentrations were about 15% lower than pretreatment. Despite stopping treatment, concentrations continued to decrease and were more than 25% lower by day 8 posttreatment. In Group EE30, LNG150, CP concentrations were significantly higher than pretreatment by days 2-3 and values continued to increase to the day of treatment. Women in Groups EE35, NET 1000 and EE35, NET600 showed a similar pattern, but the maximum percentage increase was higher, about 100%, compared to 75% in Group EE30, LNG150. Differences in the responses of ostensibly closely related proteins of hepatic origin, i.e., SHBG and CP, to the OCs demonstrate that neither can be extrapolated to other pharmacodynamic responses. OABL- eng OTO - PIP OT - Biology OT - *Clinical Research OT - *Contraception OT - Contraceptive Agents OT - *Contraceptive Agents, Female OT - Contraceptive Methods--side effects OT - Economic Factors OT - *Family Planning OT - *Oral Contraceptives--side effects OT - Physiology OT - *Proteins OT - *Research And Development OT - Research Methodology OT - Technology GN - PIP: TJ: CONTRACEPTION. EDAT- 1989/04/01 00:00 MHDA- 1989/04/01 00:01 CRDT- 1989/04/01 00:00 PHST- 1989/04/01 00:00 [pubmed] PHST- 1989/04/01 00:01 [medline] PHST- 1989/04/01 00:00 [entrez] AID - 0010-7824(89)90117-0 [pii] AID - 10.1016/0010-7824(89)90117-0 [doi] PST - ppublish SO - Contraception. 1989 Apr;39(4):385-99. doi: 10.1016/0010-7824(89)90117-0.